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OBJECTIVE: The aim of this study was to establish the
epidemiological features of agitation and aggressiveness
in patients aged 65 years or older and living at home and
what the etiological factors might be, to begin a cost
analysis in the absence of published data. 
METHODS: Prevalence was estimated, first, in a random
sample of 3777 elderly subjects (the PAQUID cohort), us-
ing DSM-III criteria and psychologists’ reports, at differ-
ent timepoints; second, in the patients of a nationally rep-
resentative sample from 159 general practitioners, from
diagnoses based on behaviors and clinical scrutiny. A na-
tional retrospective study including 410 patients was con-
ducted to investigate the consequences of symptoms such
as somatic troubles, social disability and dependence. Dis-
ability was also evaluated in the PAQUID cohort with the
AGGIR scale used to identify patients eligible to a depen-
dence-specific benefit. Risk factors (age, gender, medical
variables, etc.) were examined.
RESULTS: In 1997, the prevalence of agitation and aggres-
siveness ranged between 0.19% and 0.34% of the French
population. Of concerned subjects, 55% presented two to
three somatic troubles, 97% a restriction of social life, and
85% a restriction of daily activities. Prevalence depended
positively on age. Men exhibited more symptoms than
women (p  0.0001). Agitation and aggressiveness were
mainly associated with dementia and psychiatric diseases,
but demented subjects showed more physical agitation (p 
0.02), social disability, and dependence (p  0.0001).
CONCLUSION: The economic impact of agitated and
aggressive behaviors of elderly individuals should be
great due to the high degree of associated disability, and
it will likely increase in the future.
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OBJECTIVE: This study was designed to estimate the
cost incurred by French Social Security due to agitated
and aggressive behaviors of patients aged 65 years or
older, living at home.
METHODS: Economic appraisal was performed on a
representative sample of 410 patients included by 212
general practitioners in a national specific retrospective
survey. The bottom-up approach to calculating cost of
those psychotic symptoms for total population was based
on our preliminary estimation of their prevalence. The
whole direct medical costs were taken into account so as
to discover the medical costs of dependence associated
with behavior troubles. The main determinants of costs
were examined through the various profiles of patients
we pointed out.
RESULTS: In 1997, the average cost to the French Social
Security of an agitated and aggressive old patient dwell-
ing in the community was estimated at 23,513  1,665
FF. It varied with the age of patients, from 18,392 
2,642 FF in the 65–78 year age bracket to 21,920 
3,447 FF in the 88–99 year bracket, with a peak in the
group of patients aged 79–87 (29,724  2,675 FF) (p 
0.01). The average cost of demented patients (27,791 
2,239 FF) appeared to be significantly higher than that of
nondemented (18,410  2,445 FF) (p  0.005). Health-
care services at home for dependent patients were the
most costly category of service.
CONCLUSION: Our results highlight the economic in-
terest of better controlling behavior disorders with special
emphasis on demented patients in order to prevent them
from becoming dependent.
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BACKGROUND: Schizophrenia imposes a heavy eco-
nomic burden due to its early onset, high morbidity and
mortality, chronicity, and limited response to traditional
pharmacotherapy. Newer antipsychotics such as risperi-
done improve both negative and positive symptoms, and
impact on economic and quality-of-life measures. How-
ever, the acquisition cost of risperidone is higher than
that of traditional agents. An economic evaluation was
performed to compare risperidone with oral haloperidol,
depot haloperidol, and fluphenazine, to assess relative
differences in costs and consequences. 
METHODS: A cost-utility analysis was performed using a
decision analytic model with the perspective of the Ontario
government (Canada). Probabilities including success rates,
dropouts due to adverse events, and EPS were determined
from a systematic review of the literature. Costs were ob-
tained from the provincial formulary and fee schedules,
standard lists for community resources, and hospital case
costing. Utilities were measured in 25 stable patients with
schizophrenia, using the Standard Gamble technique, and
combined with the clinical outcomes into a measure of
quality-adjusted life-years (QALYs).
